In:
Neonatology, S. Karger AG, Vol. 116, No. 4 ( 2019), p. 369-375
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 This study aimed to assess the association between antenatal corticosteroid (ACS) and in-hospital outcomes of preterm singleton appropriate for gestational age (AGA) infants according to the presence of maternal histologic chorioamnionitis (HCA). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 A retrospective study was performed with singleton AGA neonates of 23 〈 sup 〉 +0 〈 /sup 〉 to 33 〈 sup 〉 +6 〈 /sup 〉 weeks’ gestation born between 2007 and 2014. We compared the clinical outcomes according to the presence of HCA and ACS use. We also divided the ACS group into 2 groups: infants who received ACS 2–7 days before birth (optimal ACS) or not (suboptimal ACS). Multivariate logistic regression with Firth’s penalized likelihood was performed. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 In total, 254 neonates were eligible with 109 neonates with HCA (42.9%). In multivariate analysis adjusting for GA, sex, and cesarean section, ACS use was associated with reduced severe bronchopulmonary dysplasia (BPD) or death and hypotension within 7 postnatal days among the neonates with HCA. However, it was associated with increased patent ductus arteriosus (PDA) treatment. In the optimal ACS group, severe BPD or death (aOR 0.03, 95% CI 0.01–0.42), hypotension (aOR 0.02, 95% CI 0.01–0.26), and inhaled nitric oxide use (aOR 0.06, 95% CI 0.00–0.81) were lower, however, PDA treatment (aOR 8.14, 95% CI 1.20–55.24) and sepsis (aOR 6.85, 95% CI 1.02–46.07) were higher when compared with the no ACS group among HCA+ infants. Among HCA– infants, only PDA treatment was lower in the ACS group. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 In neonates with HCA, ACS treatment was associated with reduced morbidities. However, increased sepsis was associated with optimal ACS use.
Type of Medium:
Online Resource
ISSN:
1661-7800
,
1661-7819
Language:
English
Publisher:
S. Karger AG
Publication Date:
2019
detail.hit.zdb_id:
2403535-X
SSG:
12
Permalink
